Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Carbachol→

Carbachol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
51-83-2
Molecular formula
C6H15ClN2O2
Molecular weight
182.65 g/mol
Drug class
Direct-acting cholinergic agonistparasympathomimetic muscarinic and nicotinic receptor agonist
Mechanism of action
Directly stimulates cholinergic receptors in ocular tissues, causing pupillary constriction (miosis) and contraction of the ciliary muscle. Intraocular pressure reduction is associated with increased aqueous-humour outflow; product-specific combinations may use a pinhole effect to improve near visual acuity.
Indications / reported uses
  • Induction of miosis during ophthalmic surgery and reduction of intraocular pressure in selected ophthalmic indications, depending on the formulation
  • In combination with brimonidine in the authorised ophthalmic product for presbyopia in adults; do not attribute the fixed-combination indication to carbachol monotherapy

Sources: US DailyMed — Miostat (carbachol intraocular solution) · US DailyMed — Carbachol/brimonidine ophthalmic product · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Direct-acting cholinergic agonist; parasympathomimetic muscarinic and nicotinic receptor agonist

Mechanism of action

Directly stimulates cholinergic receptors in ocular tissues, causing pupillary constriction (miosis) and contraction of the ciliary muscle. Intraocular pressure reduction is associated with increased aqueous-humour outflow; product-specific combinations may use a pinhole effect to improve near visual acuity.

General use cases

  • Induction of miosis during ophthalmic surgery and reduction of intraocular pressure in selected ophthalmic indications, depending on the formulation
  • In combination with brimonidine in the authorised ophthalmic product for presbyopia in adults; do not attribute the fixed-combination indication to carbachol monotherapy

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Carbachol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Carbachol Permitted Daily Exposure (PDE) report (the Carbachol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Carbachol Occupational Exposure Limit (OEL) report (the Carbachol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.